| 5.275 2.795 (112.7%) | 06-16 13:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.7 |
1-year : | 10.16 |
| Resists | First : | 7.44 |
Second : | 8.7 |
| Pivot price | 3 |
|||
| Supports | First : | 4.16 |
Second : | 2.13 |
| MAs | MA(5) : | 2.98 |
MA(20) : | 3.01 |
| MA(100) : | 4.02  |
MA(250) : | 6.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 30.4 |
| RSI | RSI(14): 75.7 |
|||
| 52-week | High : | 13.13 | Low : | 2.13 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CRVO ] has closed above the upper band by 35.3%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 116.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.66 - 2.67 | 2.67 - 2.69 |
| Low: | 2.4 - 2.41 | 2.41 - 2.42 |
| Close: | 2.46 - 2.48 | 2.48 - 2.5 |
CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.
Tue, 16 Jun 2026
CRVO Stock Pops As CervoMed Extends Runway And Insider Buys Big - StocksToTrade
Tue, 16 Jun 2026
CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase - TechStock²
Tue, 16 Jun 2026
CRVO Stock Draws Traders As Insider Buying Follows Financing Deal - timothysykes.com
Mon, 15 Jun 2026
CervoMed (CRVO) major holder Boger discloses 19.99% ownership stake - Stock Titan
Mon, 15 Jun 2026
Boger family trusts boost CervoMed (CRVO) stake with 955K-unit private deal - Stock Titan
Mon, 15 Jun 2026
CervoMed (NASDAQ: CRVO) updates investor presentation for use in meetings - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 6.29e+006 (%) |
| Held by Institutions | 32.8 (%) |
| Shares Short | 282 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 488.8 % |
| Return on Equity (ttm) | -72.5 % |
| Qtrly Rev. Growth | 2.09e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -20.97 |
| Dividend | 0 |
| Forward Dividend | 262810 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|